PEDIATRICS Vol. 63 No. 4 April 1979, pp. 612-615
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crosley, C. J.
Right arrow Articles by Swender, P. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crosley, C. J.
Right arrow Articles by Swender, P. T.

Dystonia Associated With Carbamazepine Administration: Experience in Brain-Damaged Children

Carl J. Crosley M.D.1 and Phillip T. Swender M.D.1

1 Departments of Neurology and Pediatrics, Upstate Medical Center SUNY, Syracuse, New York

Carbamazepine is an anticonvulsant most effective in treating complex partial and generalized tonicclonic seizures. We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use. The patients, a 4-year-old with microcephalv and severe retardation, a 1-year-old with cerebral dvsgenesis, and a 5-year-old with spastic quadriplegia and mild retardation, all had seizures unresponsive to multiple anticonvulsant combinations. In all three patients carbamazepine was introduced and gradually increased to a maximum dosage of 25 mg/kg of body weight per day. Dvstonic symptoms began two to three weeks after introduction of therapy and subsided within three weeks after discontinuation. In one child, a second course of carbamazepine resulted in a return of the dystonia. The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.

Submitted on May 11, 1978
Accepted on June 29, 1978




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C Zadikoff, R P Munhoz, A N Asante, N Politzer, R Wennberg, P Carlen, and A Lang
Movement disorders in patients taking anticonvulsants
J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 147 - 151.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. A Pina and P. J Modrego
Dystonia Induced by Gabapentin
Ann. Pharmacother., February 1, 2005; 39(2): 380 - 382.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
A. Lacayo and N. Mitra
Report of a Case of Phenobarbital-Induced Dystonia
Clinical Pediatrics, April 1, 1992; 31(4): 252 - 252.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
E. Arnstein
Oculogyric Crisis: A Distinct Toxic Effect of Carbamazepine
J Child Neurol, July 1, 1986; 1(3): 289 - 290.
[PDF]